UHRF1 and lymphoma: Our data revealed that N3a-treatment may directly lead to increase in the master epigenetic conductor UHRF1 and its privileged partner DNMT1, over-expressed in different cancer types [51] and lymphomas [52], promoting cell growth inhibition.